Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02038764 · ClinicalTrials.gov registry record · Phase 1
A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes
A Phase 1 study of Diabetes Mellitus, Type 1, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 20
- Study locations
NCT02038764: Completed Phase 1 study of Diabetes Mellitus, Type 1, sponsored by Pfizer.
NCT02038764 is a Phase 1 study of Diabetes Mellitus, Type 1 that has completed, run by Pfizer. The registered enrollment target is 37 participants, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02038764, a Phase 1 study of Diabetes Mellitus, Type 1, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.
Primary Outcome
Number of participants with dose limiting or intolerable treatment related adverse events (AEs) was reported. An AE was any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL PF-06342674 Dose A
- BIOLOGICAL PF-06342674 Dose B
- BIOLOGICAL PF-06342674 Dose C
- BIOLOGICAL PF-06342674 Dose D
Study Locations (20)
Illinois
- Duchossois Center for Advanced Medicine - Chicago
- The University of Chicago Medical Center - Chicago
- University of Chicago Clinical Resource Center - Chicago
- University of Chicago Medical Center - Chicago
California
- VA San Diego Healthcare System (Drug Shipment) - San Diego
- Veterans Administration San Diego Healthcare System - San Diego
- University of California, San Francisco - San Francisco
Connecticut
- Yale School of Medicine - New Haven
- Yale New Haven Hospital - Investigational Drug Services - New Haven
- Yale University School of Medicine - New Haven
Missouri
- Barnes- Jewish HOSP Att: Kathryn Vehe - St Louis
- Washington University - Center for Advanced Medicine - St Louis
- Washington University - St Louis
Massachusetts
- Umass Memorial Medical Center - Worcester
- University of Massachusetts Medical School - Worcester
Minnesota
- University Of Minnesota Fairview Pharmacy Services - Minneapolis
- University Of Minnesota Medical School - Minneapolis
Colorado
- Barbara Davis Center - Aurora
Georgia
- Atlanta Diabetes Associates - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2014-06-04 |
| Est. Completion | 2016-09-13 |
| Phase | Phase 1 |
What the finished NCT02038764 record still lists
NCT02038764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 1,266-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02038764 names 20 study sites across 9 states, led by Illinois, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02038764 about?
NCT02038764 is a clinical study titled "A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.
What is the current status of trial NCT02038764?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2014-06-04. Estimated completion is 2016-09-13.
What conditions does trial NCT02038764 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT02038764?
The interventions under investigation include: Placebo (DRUG), PF-06342674 Dose A (BIOLOGICAL), PF-06342674 Dose B (BIOLOGICAL), PF-06342674 Dose C (BIOLOGICAL), PF-06342674 Dose D (BIOLOGICAL).
Who is sponsoring clinical trial NCT02038764?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02038764 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02038764's enrollment target sits among peer trials
37 84th of 118 higher than 32 of 118 other Diabetes Mellitus, Type 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes
RECRUITING · Phase 1
-
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
RECRUITING · Phase 1
-
Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells
RECRUITING · Phase 1
-
Allogenic Islet Cell Transplantation
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI